ESLA: Estrella Bio Price to Sales

Corporate company logo of Estrella Immunopharma Inc (ESLA)

Estrella Immunopharma (ESLA) develops CAR-T cells with a protective mechanism for the treatment of oncohematology. The delivery of live biomaterials relies on strict cryogenic standards. The company is currently accelerating trials of the ARTEMIS therapy against CD19 to reduce the risk of complications. The value of represents the latest metric reading, allowing for an analysis of investment potential through a P/S business valuation.

Estrella Immunopharma Corp (ESLA): Market Cap to Revenue from 07/04/2022 to 11/14/2026

Analytical breakdowns for Estrella Immunopharma Inc (ESLA)

- stock price and consensus target price:
Share Price Estrella Immunopharma, Inc.|ESLA - Analyst Consensus Forecast
- market capitalization information:
Market Value Estrella Immunopharma|ESLA - Total Company Value
- shareholders' equity book value data:
Net Assets per Share Estrella Immunopharma|ESLA - Company Net Assets|Market Cap to Book Value Multiple estrellabio.com|ESLA - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Estrella Immunopharma|ESLA - Long-Term Debt to Capital|Current Liabilities to Capital estrellabio.com|ESLA - Company Debts|Debt to Book Capitalization Ratio Estrella Immunopharma|ESLA - Company Long-Term Debt|Company Short-Term Debt Estrella Immunopharma|Quick Ratio estrellabio.com
- net income and valuation ratios data:
ESLA - Net Income|Expected Net Income Estrella Immunopharma|ESLA - P/E Multiple|Market Cap to Projected Earnings Estrella Immunopharma Corp|ESLA - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Estrella Immunopharma|ESLA - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Estrella Immunopharma|ESLA - Net earnings per share for the last 12 months|Quarterly EPS earnings growth estrellabio.com|ESLA - Earnings per share growth in current year|Projected earnings per share growth rate for next year Estrella Immunopharma
- sales revenue and business income indicators:
ESLA - Company Revenue|Company Expected Sales Volume Estrella Immunopharma Inc|ESLA - Price-to-Revenue Ratio|Future Price to Revenue Estrella Immunopharma Corp
Fundamental company analysis:Estrella Immunopharma Inc ESLA
Finished products of Estrella Immunopharma, Inc.

The diversified immunotherapy pipeline of Estrella Immunopharma (ESLA) reduces clinical risks, impacting the market value of its assets. The P/S ratio, equal to , is calculated as the ratio of total market capitalization to annual revenue, measuring the premium for future sales growth. It is critical for investors to compare this multiple with the development rates of oncology targets to assess whether the asset is overbought. Analyzing the capitalization-to-revenue ratio allows for the differentiation of price volatility from actual changes in revenue.

Competitors of Estrella Immunopharma

TG Therapeutics Corp - Market Cap to Revenue Ratio|P/S Multiple ACLX (Arcellx Inc)|IRON: Market Cap to Revenue Ratio|SNDX: Market Cap to Revenue|KURA - P/S Multiple|ADCT: P/S Multiple|Price-to-Revenue Multiple Foghorn Therapeutics, Inc. FHTX|VOR (Vor Bio) - P/S Multiple|NKTX: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue COEP (Coeptis Therapeutics)|Actinium Pharmaceuticals - Market Cap to Revenue Ratio|Price-to-Revenue Ratio CASI Pharmaceuticals Inc. CASI|Market Capitalization-to-Revenue Ratio MRKR|Market Capitalization-to-Revenue Ratio IN8bio Inc. (INAB)|Market Capitalization-to-Revenue Ratio ERNA (Eterna Therapeutics, Inc.)|GTBP: P/S Multiple|APTO (Aptose Biosciences Inc) - Price-to-Revenue Ratio|Market Cap to Revenue BPTH|Market Cap to Revenue MEI Pharma (MEIP)|P/S Multiple VINC